|Dr. Ton Logtenberg||Pres, CEO, Principal Financial Officer & Exec. Director||N/A||N/A||1958|
|Mr. John de Kruif Ph.D.||CTO & Sr. VP||N/A||N/A||1964|
|Mr. Mark Throsby Ph.D.||Chief Scientific Officer & Exec. VP||N/A||N/A||1967|
|Mr. Peter B. Silverman J.D.||Exec. VP, Gen. Counsel & Chief Intellectual Property Officer||N/A||N/A||1978|
|Mr. Alexander Berthold Hendirk Bakker Ph.D.||CDO & Sr. VP||N/A||N/A||1967|
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II clinical trial for the treatment of gastric and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for the treatment of solid tumors with an initial focus on colorectal cancer. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore new potential combination therapies or indication. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Merus N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.